Unraveling the mysteries of serum albumin-more than just a serum protein

Frontiers in Physiology

Volumn 5 AUG, Issue , 2014, Pages

  Merlot, Angelica M ^a   Kalinowski, Danuta S ^a   Richardson, Des R ^a  

^a University of Sydney   (Australia)

Author keywords

Albumin drug carriers; Albumin receptors; Albumin binding proteins; gp60; Serum albumin; Tumors

Indexed keywords

ALBUMIN; ALBUMIN BINDING PROTEIN; BINDING PROTEIN; CALRETICULIN; CUBILIN; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; DRUG CARRIER; FC RECEPTOR; GEMCITABINE; GLYCOPROTEIN GP 18; GLYCOPROTEIN GP 30; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HUMAN SERUM ALBUMIN; MEGALIN; OSTEONECTIN; PACLITAXEL; RAFFINOSE; RAS PROTEIN; RNA BINDING PROTEIN; SERUM ALBUMIN; THIOSEMICARBAZONE DERIVATIVE; TRITIUM; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALBUMIN BLOOD LEVEL; ARTICLE; BIOACCUMULATION; CANCER CELL; CATABOLISM; CELL PROLIFERATION; CELLULAR DISTRIBUTION; DRUG DELIVERY SYSTEM; HUMAN; INTERSTITIUM; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NONHUMAN; PANCREAS ADENOCARCINOMA; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; TUMOR MICROENVIRONMENT;

EID: 84906519506     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2014.00299     Document Type: Article

References (75)

1. Amsellem, S., Gburek, J., Hamard, G., Nielsen, R., Willnow, T. E., Devuyst, O., et al. (2010). Cubilin is essential for albumin reabsorption in the renal proximal tubule. J. Am. Soc. Nephrol. 21, 1859-1867. doi: 10.1681/ASN.2010050492
2. Andersen, J. T., Dalhus, B., Cameron, J., Daba, M. B., Plumridge, A., Evans, L., et al. (2012). Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat. Commun. 3, 610. doi: 10.1038/ncomms1607
3. Anderson, C. L., Chaudhury, C., Kim, J., Bronson, C. L., Wani, M. A., and Mohanty, S. (2006). Perspective-FcRn transports albumin: relevance to immunology and medicine. Trends Immunol. 27, 343-348. doi: 10.1016/j.it.2006.05.004
4. Andersson, C., Iresjo, B. M., and Lundholm, K. (1991). Identification of tissue sites for increased albumin degradation in sarcoma-bearing mice. J. Surg. Res. 50, 156-162. doi: 10.1016/0022-4804(91)90240-M
5. Birn, H., Fyfe, J. C., Jacobsen, C., Mounier, F., Verroust, P. J., Orskov, H., et al. (2000). Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. J. Clin. Invest. 105, 1353-1361. doi: 10.1172/JCI8862
6. Brekken, R. A., and Sage, E. H. (2001). SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 19, 816-827. doi: 10.1016/S0945-053X(00)00133-5
7. Carmeliet, P., and Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257. doi: 10.1038/35025220
8. Chaudhury, A., Chander, P., and Howe, P. H. (2010). Heterogeneous nuclear ribonucleoproteins (hnRNPs) in cellular processes: focus on hnRNP E1's multifunctional regulatory roles. RNA 16, 1449-1462. doi: 10.1261/rna.2254110
9. Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C., et al. (2003). The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J. Exp. Med. 197, 315-322. doi: 10.1084/jem.20021829
10. Christensen, E. I., and Birn, H. (2002). Megalin and cubilin: multifunctional endocytic receptors. Nat. Rev. Mol. Cell Biol. 3, 256-266. doi: 10.1038/nrm778
11. Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., et al. (2013). Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497, 633-637. doi: 10.1038/nature12138
12. Cui, S., Verroust, P. J., Moestrup, S. K., and Christensen, E. I. (1996). Megalin/gp330 mediates uptake of albumin in renal proximal tubule. Am. J. Physiol. 271, F900-F907. doi: 10.1038/nature12138
13. Dennis, M. S., Zhang, M., Meng, Y. G., Kadkhodayan, M., Kirchhofer, D., Combs, D., et al. (2002). Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. 277, 35035-35043. doi: 10.1074/jbc.M205854200
14. Desai, N., Trieu, V., Damascelli, B., and Soon-Shiong, P. (2009). SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl. Oncol. 2, 59-64. doi: 10.1593/tlo.09109
15. Desai, N. P., Trieu, V., Hwang, L. Y., Wu, R., Soon-Shiong, P., and Gradishar, W. J. (2008). Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 19, 899-909. doi: 10.1097/CAD.0b013e32830f9046
16. Evans, T. W. (2002). Review article: albumin as a drug-biological effects of albumin unrelated to oncotic pressure. Aliment. Pharmacol. Ther. 16(Suppl. 5), 6-11. doi: 10.1046/j.1365-2036.2002.00190.x
17. Fritzsche, T., Schnolzer, M., Fiedler, S., Weigand, M., Wiessler, M., and Frei, E. (2004). Isolation and identification of heterogeneous nuclear ribonucleoproteins (hnRNP) from purified plasma membranes of human tumour cell lines as albumin-binding proteins. Biochem. Pharmacol. 67, 655-665. doi: 10.1016/j.bcp.2003.09.027
18. Ghinea, N., Eskenasy, M., Simionescu, M., and Simionescu, N. (1989). Endothelial albumin binding proteins are membrane-associated components exposed on the cell surface. J. Biol. Chem. 264, 4755-4758.
19. Ghinea, N., Fixman, A., Alexandru, D., Popov, D., Hasu, M., Ghitescu, L., et al. (1988). Identification of albumin-binding proteins in capillary endothelial cells. J. Cell Biol. 107, 231-239.
20. Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., et al. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794-7803. doi: 10.1200/JCO.2005.04.937
21. Graham, J. M. (2002). Preparation of crude subcellular fractions by differential centrifugation. ScientificWorldJournal 2, 1638-1642. doi: 10.1100/tsw.2002.851
22. Grasbeck, R. (2006). Imerslund-Grasbeck syndrome (selective vitamin B(12) malabsorption with proteinuria). Orphanet. J. Rare Dis. 1:17. doi: 10.1186/1750-1172-1-17
23. Greish, K. (2007). Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target. 15, 457-464. doi: 10.1080/10611860701539584
24. Han, N., Li, W., and Zhang, M. (2013). The function of the RNA-binding protein hnRNP in cancer metastasis. J. Cancer Res. Ther. 9(Suppl.), S129-S134. doi: 10.4103/0973-1482.122506
25. Hawkins, J. W., and Dugaiczyk, A. (1982). The human serum albumin gene: structure of a unique locus. Gene 19, 55-58. doi: 10.1016/0378-1119(82)90188-3
26. He, X. M., and Carter, D. C. (1992). Atomic structure and chemistry of human serum albumin. Nature 358, 209-215. doi: 10.1038/358209a0
27. Hradec, J. (1958). Metabolism of serum albumin in tumour-bearing rats. Br. J. Cancer 12, 290-304. doi: 10.1038/bjc.1958.35
28. Iancu, C., Mocan, L., Bele, C., Orza, A. I., Tabaran, F. A., Catoi, C., et al. (2011). Enhanced laser thermal ablation for the in vitro treatment of liver cancer by specific delivery of multiwalled carbon nanotubes functionalized with human serum albumin. Int. J. Nanomed. 6, 129-141. doi: 10.2147/IJN.S15841
29. Iwamoto, T. (2013). Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. Biol. Pharm. Bull. 36, 715-718. doi: 10.1248/bpb.b12-01102
30. Jain, R. K. (2001). Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7, 987-989. doi: 10.1038/nm0901-987
31. Kragh-Hansen, U. (1981). Molecular aspects of ligand binding to serum albumin. Pharmacol. Rev. 33, 17-53. doi: 10.1038/nm0901-987
32. Kratz, F. (2008). Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 132, 171-183. doi: 10.1016/j.jconrel.2008.05.010
33. Kratz, F. (2010). Albumin, a versatile carrier in oncology. Int. J. Clin. Pharmacol. Ther. 48, 453-455. doi: 10.5414/CPP48453
34. Kudlowitz, D., and Muggia, F. (2014). Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications. Expert Opin. Drug Saf. 13, 681-685. doi: 10.1517/14740338.2014.910193
35. Lancon, A., Delmas, D., Osman, H., Thenot, J. P., Jannin, B., and Latruffe, N. (2004). Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem. Biophys. Res. Comm. 316, 1132-1137. doi: 10.1016/j.bbrc.2004.02.164
36. Lovejoy, D. B., Jansson, P. J., Brunk, U. T., Wong, J., Ponka, P., and Richardson, D. R. (2011). Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res. 71, 5871-5880. doi: 10.1158/0008-5472.CAN-11-1218
37. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., and Hori, K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65, 271-284. doi: 10.1016/S0168-3659(99)00248-5
38. Matsumura, Y., and Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392.
39. Mendlovic, F., and Conconi, M. (2010). Calreticulin: a multifaceted protein. Nature Educ. 4, 1.
40. Merlot, A. M., Kalinowski, D. S., and Richardson, D. R. (2013a). Novel chelators for cancer treatment: where are we now? Antioxid. Redox Signal. 18, 973-1006. doi: 10.1089/ars.2012.4540
41. Merlot, A. M., Pantarat, N., Menezes, S. V., Sahni, S., Richardson, D. R., and Kalinowski, D. S. (2013b). Cellular uptake of the antitumor agent Dp44mT occurs via a carrier/receptor-mediated mechanism. Mol. Pharmacol. 84, 911-924. doi: 10.1124/mol.113.088393
42. Merlot, A. M., and Richardson, D. R. (2014). Receptor recognition and lysosomal targeting to enhance cytotoxicity of novel anti-cancer agents that bind iron and copper. Vitam. Miner. 3:e125. doi: 10.4172/vms.1000e125
43. Milici, A. J., Watrous, N. E., Stukenbrok, H., and Palade, G. E. (1987). Transcytosis of albumin in capillary endothelium. J. Cell Biol. 105, 2603-2612.
44. Moestrup, S. K., Kozyraki, R., Kristiansen, M., Kaysen, J. H., Rasmussen, H. H., Brault, D., et al. (1998). The intrinsic factor-vitamin B12 receptor and target of teratogenic antibodies is a megalin-binding peripheral membrane protein with homology to developmental proteins. J. Biol. Chem. 273, 5235-5242. doi: 10.1074/jbc.273.9.5235
45. Neesse, A., Frese, K. K., Chan, D. S., Bapiro, T. E., Howat, W. J., Richards, F. M., et al. (2014). SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut 63, 974-983. doi: 10.1136/gutjnl-2013-305559
46. Ober, R. J., Martinez, C., Lai, X., Zhou, J., and Ward, E. S. (2004). Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc. Natl. Acad. Sci. U.S.A. 101, 11076-11081. doi: 10.1073/pnas.0402970101
47. Peters, T. (1996). All About Albumin: Biochemistry, Genetics and Medical Applications. San Diego, CA: Academic Press Limited.
48. Peterson, H. I., and Appelgren, K. L. (1973). Experimental studies on the uptake and rentention of labelled proteins in a rat tumour. Eur. J. Cancer 9, 543-547. doi: 10.1016/0014-2964(73)90142-4
49. Podhajcer, O. L., Benedetti, L. G., Girotti, M. R., Prada, F., Salvatierra, E., and Llera, A. S. (2008). The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev. 27, 691-705. doi: 10.1007/s10555-008-9146-7
50. Porter, P. L., Sage, E. H., Lane, T. F., Funk, S. E., and Gown, A. M. (1995). Distribution of SPARC in normal and neoplastic human tissue. J. Histochem. Cytochem. 43, 791-800. doi: 10.1177/43.8.7622842
51. Roopenian, D. C., and Akilesh, S. (2007). FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715-725. doi: 10.1038/nri2155
52. Sarav, M., Wang, Y., Hack, B. K., Chang, A., Jensen, M., Bao, L., et al. (2009). Renal FcRn reclaims albumin but facilitates elimination of IgG. J. Am. Soc. Nephrol. 20, 1941-1952. doi: 10.1681/ASN.2008090976
53. Schilling, U., Friedrich, E. A., Sinn, H., Schrenk, H. H., Clorius, J. H., and Maier-Borst, W. (1992). Design of compounds having enhanced tumour uptake, using serum albumin as a carrier-Part II. In vivo studies. Int. J. Rad. Appl. Instrum. B 19, 685-695. doi: 10.1016/0883-2897(92)90103-6
54. Schnitzer, J. E. (1992). gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am. J. Physiol. 262, H246-H254. doi: 10.1016/1050-1738(93)90012-U
55. Schnitzer, J. E. (1993). Update on the cellular and molecular basis of capillary permeability. Trends Cardiovasc. Med. 3, 124-130. doi: 10.1016/1050-1738(93)90012-U
56. Schnitzer, J. E., Allard, J., and Oh, P. (1995). NEM inhibits transcytosis, endocytosis, and capillary permeability: implication of caveolae fusion in endothelia. Am. J. Physiol. 268, H48-H55.
57. Schnitzer, J. E., and Bravo, J. (1993). High affinity binding, endocytosis, and degradation of conformationally modified albumins. Potential role of gp30 and gp18 as novel scavenger receptors. J. Biol. Chem. 268, 7562-7570.
58. Schnitzer, J. E., Carley, W. W., and Palade, G. E. (1988). Albumin interacts specifically with a 60-kDa microvascular endothelial glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 85, 6773-6777. doi: 10.1073/pnas.85.18.6773
59. Schnitzer, J. E., and Oh, P. (1992). Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium. Am. J. Physiol. 263, H1872-H1879.
60. Schnitzer, J. E., and Oh, P. (1994). Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins. J. Biol. Chem. 269, 6072-6082.
61. Schnitzer, J. E., Sung, A., Horvat, R., and Bravo, J. (1992). Preferential interaction of albumin-binding proteins, gp30 and gp18, with conformationally modified albumins. Presence in many cells and tissues with a possible role in catabolism. J. Biol. Chem. 267, 24544-24553.
62. Seetharam, B., Christensen, E. I., Moestrup, S. K., Hammond, T. G., and Verroust, P. J. (1997). Identification of rat yolk sac target protein of teratogenic antibodies, gp280, as intrinsic factor-cobalamin receptor. J. Clin. Invest. 99, 2317-2322. doi: 10.1172/JCI119411
63. Sinn, H., Schrenk, H. H., Friedrich, E. A., Schilling, U., and Maier-Borst, W. (1990). Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part I. Int. J. Rad. Appl. Instrum. B 17, 819-827. doi: 10.1016/0883-2897(92)90103-6
64. Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., et al. (2012). Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J. Clin. Oncol. 30, 2055-2062. doi: 10.1200/JCO.2011.39.5848
65. Stehle, G., Sinn, H., Wunder, A., Schrenk, H. H., Stewart, J. C., Hartung, G., et al. (1997). Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia. Crit. Rev. Oncol. Hematol. 26, 77-100. doi: 10.1016/S1040-8428(97)00015-2
66. Sudlow, G., Birkett, D. J., and Wade, D. N. (1976). Further characterization of specific drug binding sites on human serum albumin. Mol. Pharmacol. 12, 1052-1061.
67. Sugio, S., Kashima, A., Mochizuki, S., Noda, M., and Kobayashi, K. (1999). Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng. 12, 439-446. doi: 10.1093/protein/12.6.439
68. Tiruppathi, C., Finnegan, A., and Malik, A. B. (1996). Isolation and characterization of a cell surface albumin-binding protein from vascular endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 93, 250-254. doi: 10.1073/pnas.93.1.250
69. Tiruppathi, C., Song, W., Bergenfeldt, M., Sass, P., and Malik, A. B. (1997). Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J. Biol. Chem. 272, 25968-25975. doi: 10.1074/jbc.272.41.25968
70. van der Veldt, A. A., Luurtsema, G., Lubberink, M., Lammertsma, A. A., and Hendrikse, N. H. (2008). Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance. Curr. Pharm. Des. 14, 2914-2931. doi: 10.2174/138161208786404344
71. Vuignier, K., Schappler, J., Veuthey, J. L., Carrupt, P. A., and Martel, S. (2010). Drug-protein binding: a critical review of analytical tools. Anal. Bioanal. Chem. 398, 53-66. doi: 10.1007/s00216-010-3737-1
72. Wang, J., Ueno, H., Masuko, T., and Hashimoto, Y. (1994). Binding of serum albumin on tumor cells and characterization of the albumin binding protein. J. Biochem. 115, 898-903.
73. Wunder, A., Stehle, G., Sinn, H., Schrenk, H., Hoffbiederbeck, D., Bader, F., et al. (1997). Enhanced albumin uptake by rat tumors. Int. J. Oncol. 11, 497-507. doi: 10.3892/ijo.11.3.497
74. Yamagishi, T., Sahni, S., Sharp, D. M., Arvind, A., Jansson, P. J., and Richardson, D. R. (2013). P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J. Biol. Chem. 288, 31761-31771. doi: 10.1074/jbc.M113.514091
75. Zhai, X. Y., Nielsen, R., Birn, H., Drumm, K., Mildenberger, S., Freudinger, R., et al. (2000). Cubilin- and megalin-mediated uptake of albumin in cultured proximal tubule cells of opossum kidney. Kidney Int. 58, 1523-1533. doi: 10.1046/j.1523-1755.2000.00314.x